Credit Suisse Downgrades Allena Pharmaceuticals to Neutral, Lowers Price Target to $4

Credit Suisse downgrades Allena Pharmaceuticals (NASDAQ:ALNA) from Outperform to Neutral and lowers the price target from $7 to $4.

Benzinga · 11/08/2019 11:05

Credit Suisse downgrades Allena Pharmaceuticals (NASDAQ:ALNA) from Outperform to Neutral and lowers the price target from $7 to $4.